Moreover, Ad-ΔB/TRAIL and Ad-ΔB/IL-12 combination treatment additively reduced vascular endothelial growth factor (VEGF) and CD31 expression as well as the microvessel density in the tumor tissues. This evidence concerns the gene TNFSF10 and neoplasm.